• The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Initial lymphoma stage and number of previous treatment lines were identified as independent risk factors for EFS in DLBCL and HL patients. (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma and is the newest addition to the company's generic injectable oncology medicine portfolio, the largest in U.S. health care. (fresenius-kabi.com)
  • Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). (fresenius-kabi.com)
  • 211At conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. (fredhutch.org)
  • The hematopoietic stem cells (CD34+ cells) are collected from the peripheral blood and used for autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma . (drugs.com)
  • Primary diagnoses were multiple myeloma (n = 14), Hodgkin's lymphoma (n = 7), non-Hodgkin's lymphoma (n = 2), acute myloid leukemia (n = 2), chronic lymphocytic leukemia (n = 1) and germ cell testis tumor (n = 1). (ogu.edu.tr)
  • FDA granted accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (org.in)
  • FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (org.in)
  • FDA approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (org.in)
  • FDA granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. (org.in)
  • FDA granted accelerated approval to mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (org.in)
  • FDA approved brentuximab vedotin (Adcetris, Seagen, Inc.) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma (cHL). (org.in)
  • HDC with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. (bdbiosciences.com)
  • A stem cell transplant is often the best option to treat blood cancers, such as leukemia , lymphoma and multiple myeloma , as well as bone marrow failure syndromes like myelodysplastic syndrome . (mdanderson.org)
  • Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. (smw.ch)
  • Our center provides personalized, compassionate care to patients with leukemia, lymphoma, multiple myeloma, and other blood-related conditions. (koruhastanesi.com)
  • Autologous BMT is used as a salvage therapy for patients with relapsed or refractory Hodgkin's lymphoma. (koruhastanesi.com)
  • Autologous BMT is used as a consolidation therapy for patients with high-risk non-Hodgkin's lymphoma. (koruhastanesi.com)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
  • Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
  • For example, absolute lymphocyte counts (ALCs), a simple laboratory parameter that is routinely evaluated in the clinical setting, has been found to be associated with treatment outcomes in patients with diffuse large B cell lymphoma, follicular lymphoma, or acute leukemias ( Am J Hematol 84(2) (2009)">1 - Br J Haematol 134(6) (2006)">3 ). (cancerdiagnosisprognosis.org)
  • Bone marrow cancers such as multiple myeloma , leukaemia, and lymphoma , reduce the formation of HSCs in the bone marrow. (parkwaycancercentre.com)
  • Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
  • Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
  • it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (wikipedia.org)
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • There is a need for further investigation into the effects of and guidelines for exercise interventions (especially strength training) in this population of patients, particularly among cancer patients who are undergoing or have undergone chemotherapy or radiation treatments. (karger.com)
  • Dimeo F, Schwartz S, Fietz T, Wanjura T, Boning D, Thiel E: Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy. (karger.com)
  • Dimeo FC, Tilmann MH, Bertz H, Kanz L, Mertelsmann R, Keul J: Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. (karger.com)
  • Dolan LB, Gelmon K, Courneya KS, Mackey JR, Segal RJ, Lane K, Reid RD, McKenzie DC: Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy. (karger.com)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • 3.2 mg/kg/day busulfan on days -5 to -3 and 140 mg/m 2 /day melphalan on day -2) in patients with multiple myeloma (MM) following bortezomib-based induction chemotherapy. (elsevierpure.com)
  • Results showed that adding quizartinib to standard chemotherapy with or without allogeneic hematopoietic stem cell transplantation, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival. (medscape.com)
  • FDA approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (org.in)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
  • 3 Following exogenous stimulation, such as chemotherapy or using growth factors such as granulocyte colony stimulating factor (G-CSF) and filgrastim, the number of HSCs in the peripheral blood increases, either becoming on par or even exceeding the number in the bone marrow. (bdbiosciences.com)
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • We extract blood cells, treat the cancer with high-dose chemotherapy , then place the cells back into the patient. (mdanderson.org)
  • Once the cancer is less active and the patient has been pre-treated with chemotherapy (known as conditioning), he or she receives the donor's healthy stem cells. (mdanderson.org)
  • BMT is used in combination with chemotherapy as a treatment for multiple myeloma, a cancer that affects the plasma cells in bone marrow. (koruhastanesi.com)
  • Autologous BMT involves collecting and storing a patient's own healthy stem cells, which are later transplanted back into the patient's body after chemotherapy or radiation therapy. (koruhastanesi.com)
  • Autologous BMT is commonly used in combination with chemotherapy to treat multiple myeloma. (koruhastanesi.com)
  • Peripheral blood stem cell transplantation (PBSCT) involves the collection of stem cells from the patient's blood and their subsequent infusion after chemotherapy or radiation therapy. (koruhastanesi.com)
  • PBSCT is used in combination with chemotherapy as a treatment for multiple myeloma. (koruhastanesi.com)
  • Chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. (cancertreatmenttoday.org)
  • The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
  • Stem cell therapy, or stem cell transplant, is a procedure that aims to restore blood-forming stem cells in patients who have undergone chemotherapy or radiotherapy . (parkwaycancercentre.com)
  • Autologous stem cell (patient's own stem cells) transplant is used to help patients recover from the effects of chemotherapy. (parkwaycancercentre.com)
  • Allogeneic stem cell (stem cells from a donor) transplant is used to help patients recover from the effects of chemotherapy and/or radiotherapy as well as to eradicate the remaining cancer cells in the patient after chemotherapy and/or radiotherapy. (parkwaycancercentre.com)
  • Chemotherapy or radiotherapy used to treat these cancers will destroy the HSCs in the bone marrow and abolish the body's ability to regenerate blood cells. (parkwaycancercentre.com)
  • The patient first receives a high dose of chemotherapy and/ or radiotherapy to eliminate the remaining cancer cells in the body. (parkwaycancercentre.com)
  • In allogeneic stem cell (stem cells from a donor) transplant, there is another benefit in addition to replenishing the HSCs in the bone marrow after chemotherapy or radiotherapy. (parkwaycancercentre.com)
  • Patients with early-stage CLL are not treated with chemotherapy until they become symptomatic or display evidence of rapid progression of disease. (medscape.com)
  • Chemotherapy is not needed in CLL until patients become symptomatic or display evidence of rapid progression of disease. (medscape.com)
  • Note: For transplant-eligible patients enrolled to Part 1 or Part 2, induction plus conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen. (who.int)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. (stembook.org)
  • Transplant Cell Ther. (stembook.org)
  • Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. (stembook.org)
  • Biol Blood Marrow Transplant. (stembook.org)
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • 05). Life-threatening cardiac toxicity was not significantly increased in patients with pathologic results before transplant. (slideshare.net)
  • A total of 179 transplant-eligible patients with newly diagnosed MM treated at a single academic center were included. (biomedcentral.com)
  • A hematopoietic stem cell transplant replaces faulty cells so the body can produce normal, healthy cells again. (mdanderson.org)
  • An autologous stem cell transplant uses the patient's own cells for treatment. (mdanderson.org)
  • An allogeneic stem cell transplant is similar, but we take cells from someone other than the patient. (mdanderson.org)
  • Where do allogeneic stem cell transplant donor cells come from? (mdanderson.org)
  • With a peripheral blood cell transplant, the donor receives growth factor shots to stimulate the bone marrow to push the stem cells into the blood. (mdanderson.org)
  • The cells for a cord blood transplant come from an umbilical cord collected at birth by the MD Anderson Cord Blood Bank . (mdanderson.org)
  • For many patients who don't have a well-matched, healthy donor, a cord blood transplant is a viable option. (mdanderson.org)
  • The Koru Hospital Bone Marrow Transplant Center is a state-of-the-art medical facility that offers advanced stem cell therapy for a range of hematological disorders. (koruhastanesi.com)
  • At the Koru Hospital Bone Marrow Transplant Center, we provide comprehensive care to our patients, from pre-transplant evaluation to post-transplant follow-up care. (koruhastanesi.com)
  • this should lead to better overall survival in both transplant and non-transplant patients. (medscape.com)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • During the consultation, one must consider the basic criterions starting with the most suitable type of stem cell transplant, beginning with the right form of transplants and their source. (advancells.com)
  • An Autologous transplant is used to treat some types of blood cancer. (advancells.com)
  • In this therapy, the patient's own stem cells are removed from his or her bone marrow or peripheral blood before the transplant. (advancells.com)
  • Allogeneic stem transplant is another form wherein the stem cells are donated to the person from a genetically matched stem cell donor. (advancells.com)
  • Although this form of transplant offers the best chance of curing a number of blood cancers and other serious diseases, it is much riskier than autologous transplants. (advancells.com)
  • One needs to differentiate between tandem transplants, a planned sequence of two high dose treatments with HSCT salvage, and a second transplant, an approach of consolidating the first autologous HSCT with another HSCT ONLY if the first one appears partially effective. (cancertreatmenttoday.org)
  • A tandem autologous transplant, also known as a double autologous transplant, requires the patient to undergo two planned autologous stem cell transplants within 6 months. (cancertreatmenttoday.org)
  • Stem cells are collected once before the initial transplant and half are used for each procedure. (cancertreatmenttoday.org)
  • On the other hand, for patients who have not responded completely, NCCN recommends second transplant. (cancertreatmenttoday.org)
  • After stem cell collection, EDAP (etoposide, dexamethasone, cytarabine, cisplatin) was given to enhance reduction of tumor cells prior to high-dose therapy (melphalan 200 mg/m²) and autologous transplant. (cancertreatmenttoday.org)
  • In addition, it has yet to be determined which patients benefit most from a tandem transplant. (cancertreatmenttoday.org)
  • The issue of allogeneic after autologous transplant is reviewed under a separate heading. (cancertreatmenttoday.org)
  • The phase 3 PETHEMA/GEM2012 study, in 458 patients {less than or equal to} 65 years old with NDMM, is evaluating bortezomib (subcutaneous) + lenalidomide + dexamethasone (VRD) for 6 cycles followed by autologous stem cell transplant (ASCT) conditioned with intravenous busulfan + melphalan vs melphalan and posttransplant consolidation with 2 cycles of VRD. (cun.es)
  • After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. (biomedcentral.com)
  • Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. (biomedcentral.com)
  • We describe laboratory-confirmed influenza A pandemic (H1N1) 2009 in 17 hospitalized recipients of a hematopoietic stem cell transplant (HSCT) (8 allogeneic) and in 15 patients with malignancy treated at 6 Australian tertiary centers during winter 2009. (cdc.gov)
  • The protective effect of seasonal influenza vaccination is reduced in patients with hematologic malignancy and recipients of an allogeneic hematopoietic stem cell transplant (HSCT) ( 5 , 6 ). (cdc.gov)
  • Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C. Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. (gitmo.it)
  • Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. (gitmo.it)
  • Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. (myeloma.org.uk)
  • In this context, patients experience the first psychological conflicts before this transplant. (bvsalud.org)
  • Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagn. (sparkcures.com)
  • Stem cell transplant is often a part of the treatment plan for blood cancers. (parkwaycancercentre.com)
  • The stem cells originate from the patient who will receive the transplant. (parkwaycancercentre.com)
  • A donor, either related or unrelated to the patient, who donates the stem cells for transplant. (parkwaycancercentre.com)
  • METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
  • The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT). (biomedcentral.com)
  • Peripheral blood samples were collected for measuring monocytic (M-) MDSCs (CD14 pos HLA-DR low/neg ) and early-stage (E-) MDSCs (Lin neg HLA-DR neg CD33 pos CD11b pos ) before and after ASCT. (biomedcentral.com)
  • Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
  • We propose that targeting CSF1R on these cells may improve the results of ASCT in MM. (biomedcentral.com)
  • The complete response rate of 33.4% after induction in the intent-to-treat (ITT) population, which was similar in the 92 patients with high-risk cytogenetics (34.8%), also deepened with further treatment (44.1% after ASCT and 50.2% after consolidation). (cun.es)
  • Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. (gitmo.it)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • this is used in both autologous and allogenic HSCT. (bdbiosciences.com)
  • Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. (smw.ch)
  • In this report, we summarize the case of a patient with MM status post autologous HSCT and chronic kidney disease who experienced worsening hypertension along with a substantial increase in proteinuria shortly after the initiation of carfilzomib for the treatment of refractory disease. (biomedcentral.com)
  • Ten (31.3%) patients were admitted to intensive care, and 9 of them were HSCT recipients. (cdc.gov)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • Data were collected between March and September of 2016, through the evaluation of the medical records of 43 patients who underwent HSCT and developed some type of psychological distress. (bvsalud.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • In order to better understand the LPI kinetics and its determinants and implications, we undertook sequential LPI determinations before and after conditioning until engraftment in 25 auto-HSCT patients. (karger.com)
  • One hundred patients (receiving 123 conditioning regimens) were included in the analysis. (nature.com)
  • Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. (stembook.org)
  • These findings demonstrate that bortezomib is safe and has a potential role in conditioning regimens in combination with BuMel for patients with transplantation-eligible MM. (elsevierpure.com)
  • It is indicated as monotherapy, in combination with dexamethasone, or in combination with lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma in patients who have received at least 1 prior line of therapy. (medscape.com)
  • Elranatamab is indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (medscape.com)
  • FDA granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (org.in)
  • FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (org.in)
  • A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. (biomedcentral.com)
  • We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. (biomedcentral.com)
  • Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States. (myeloma.org.uk)
  • A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. (myeloma.org.uk)
  • Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. (myeloma.org.uk)
  • Wu KL, van Wieringen W, Vellenga E, Zweegman S, Lokhorst HM, Sonneveld P. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. (rug.nl)
  • Autologous transplants have the advantage of lower risk of infection during the immune-compromised portion of the treatment, since the recovery of immune function is rapid. (wikipedia.org)
  • To understand the different types of stem cell transplants and how they work, we spoke with Borje S. Andersson, M.D., Ph.D. Here's what he had to say. (mdanderson.org)
  • What are the types of stem cell transplants? (mdanderson.org)
  • Stem cell transplants fall into two categories: autologous and allogeneic. (mdanderson.org)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
  • However, the patients must understand that stem cell transplants turn out to be successful in 50-60 per cent cases and that too just in improving the condition of the patient. (advancells.com)
  • Preliminary results of several randomized trials comparing tandem and single autologous transplants, which have not been followed as long, have also shown superior event-free survival with the tandem regimen in most studies. (cancertreatmenttoday.org)
  • It appears that in patients with poor prognostic features, outcome is not improved with tandem transplants, so additional strategies need to be evaluated in this patient population. (cancertreatmenttoday.org)
  • A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. (biomedcentral.com)
  • Frequently, stem cells are taken from the pelvic bone, filtered, and stored under special conditions for future transplants. (parkwaycancercentre.com)
  • Additionally, stem cell transplants can also be categorised based on who donates the stem cells. (parkwaycancercentre.com)
  • He has had 2 autologous stem cell transplants, 7 years and 1 year ago. (medscape.com)
  • In this regard, clinical research focused on the effect of the profile of immune system is performed among patients with hematologic malignancies and those with solid tumors. (cancerdiagnosisprognosis.org)
  • In total, 67.5% of patients reached the stem cell collection goal of 6x10 6 CD 34-positive cells/kg or more in 2 apheresis sessions by a central laboratory. (cancernetwork.com)
  • Moreover, 92.5% and 21.4% of patients reached the goal with up to 2 apheresis sessions. (cancernetwork.com)
  • Innovation in this area of medicine has been needed, and today's approval of [motixafortide] addresses the demand for new therapies that can meet today's challenges by delivering more reliability in stem cell mobilization, [vs] filgrastim alone, with fewer days of apheresis sessions and fewer doses of filgrastim for people living with this cancer. (cancernetwork.com)
  • Plerixafor may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. (fresenius-kabi.com)
  • Platelet counts should be monitored in patients who receive Plerixafor and then undergo apheresis. (fresenius-kabi.com)
  • We evaluated hematopoietic stem cells according to CD34 expression and aldehyde dehydrogenase (ALDH) activity in peripheral blood and apheresis product samples from patients after mobilization with granulocyte-colony-stimulating factor (G-CSF) alone or G-CSF after high-dose cyclophosphamide (4 g/m(2) once daily, intravenously on day 1). (ogu.edu.tr)
  • Numbers of SSClo CD45(dim) CD34(hi) cells and SSClo ALDH(br) cells were highly correlated in both peripheral blood and apheresis products (P (ogu.edu.tr)
  • Quantitating the CD34+ cell population can also be useful during mobilization as well as for determining the optimal timing of apheresis sessions to make sure that enough CD34+ cells have been harvested. (bdbiosciences.com)
  • Bortezomib is indicated for patients with multiple myeloma. (medscape.com)
  • In phase I, doses of bortezomib (.7, 1.0, and 1.3 mg/m 2 ) with BuMel were administered to groups of 3 patients each. (elsevierpure.com)
  • [ 34 ] A study by Neben et al concludes that long-term administration of bortezomib in patients with del(17p13) may result in better overall and progression-free survival. (medscape.com)
  • Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. (biomedcentral.com)
  • In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient. (biomedcentral.com)
  • Bortezomib is a proteasome inhibitor that was approved by the Food and Drug Administration (FDA) in 2003 for the treatment of refractory MM and subsequently in 2008 as an initial treatment of patients with MM. Although it does not target VEGF directly, bortezomib has also been reported to be associated with TMA. (biomedcentral.com)
  • His pioneering work spans discoveries in basic biology of blood stem cells and leukemia to first-in-human clinical trials for people with cancer and heart diseases, alongside shaping innovative policies in state health and healthcare financing. (ufl.edu)
  • FDA approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (org.in)
  • It is well known that persistent immunodeficiency is a common feature in patients with leukemia. (biomedcentral.com)
  • Moreover, it has been shown that the PD-1 ligand (PD-L1) is highly expressed in leukemia cells. (biomedcentral.com)
  • In addition, PD-1/PD-L1 interactions contribute to functional T-cell impairment, which fails to elicit minimal residual disease and may be related to leukemia relapse. (biomedcentral.com)
  • Depending on the type of leukemia, autologous or allogeneic BMT may be recommended. (koruhastanesi.com)
  • Cord blood transplantation is used as a treatment option for acute and chronic leukemia. (koruhastanesi.com)
  • A systematic review by He et al demonstrated a reduction in vertebral compressions and time to progression with early systemic treatment for asymptomatic patients, but this study also revealed an increase in acute leukemia in the early treatment group. (medscape.com)
  • Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. (uchicago.edu)
  • Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. (uchicago.edu)
  • Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. (uchicago.edu)
  • He has built a prototype of AI with neural network analysis for patients with chronic myeloid leukemia in chronic phase (CML-CP) for the best treatment decision. (mdanderson.org)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • Peripheral smear from a patient with chronic lymphocytic leukemia, small lymphocytic variety. (medscape.com)
  • 2 Evaluation of harvest adequacy requires the use of reliable progenitor cell assays and this is usually achieved by CD34 cell counting using flow cytometry. (bdbiosciences.com)
  • Flow cytometric applications for CD34+ cell identification and enumeration provide a rapid, quantitative and reproducible method to evaluate the progenitor cell population. (bdbiosciences.com)
  • A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. (fredhutch.org)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
  • however, patients who experience early relapse, or who are refractory to initial immunochemotherapy have a poor prognosis ( 3 ). (frontiersin.org)
  • Despite these clinical improvements, the vast majority of patients eventually experience disease relapse and progression. (biomedcentral.com)
  • The 2009 International Myeloma Workshop concluded that detection of any cytogenic abnormality suggests higher-risk disease, including chromosomal 13 or 13q deletion, t(4;14), and del17p and fluorescence in situ hybridization detection of t(4;14), t(14;16), and del17p. (medscape.com)
  • Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm. (cancernetwork.com)
  • While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. (biomedcentral.com)
  • Up to 80% of patients with newly diagnosed multiple myeloma. (org.in)
  • Achieving and maintaining high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). (cun.es)
  • The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment . (sparkcures.com)
  • 14: Laurell H, Hansson LE, Gunnarsson U. Impact of clinical experience and diagnostic performance in patients with acute abdominal pain. (cancercentrum.se)
  • Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. (myeloma.org.uk)
  • Safety of autologous stem cell transplantation in patients with known Human T-cell Lymphotropic Viruses Type 1 and 2 infection: A case series of four patients. (bu.edu)
  • However, safety of autologous stem cells (Cells taken from the patients' body) has been established through various trials across the globe. (advancells.com)
  • Given the strong efficacy data shown in the GENESIS trial, which included patients who are representative of the current multiple myeloma patient population, we believe [motixafortide] will play a critical role in addressing unmet needs and introduce a new treatment paradigm for this challenging cancer," Serlin stated. (cancernetwork.com)
  • A subsequent cohort with 41 patients was analyzed in a phase II trial to identify safety and efficacy. (elsevierpure.com)
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
  • In the SIMPLIFY-1 multicenter, randomized, double-blind, phase III study, safety and efficacy of momelotinib was compared with ruxolitinib in 432 patients with myelofibrosis who had not received prior treatment with a JAK inhibitor. (medscape.com)
  • This study demonstrated clinical and experimental evidences supporting a potential efficacy and safety of utilizing autologous PDL cells in the treatment of human periodontitis. (ca.gov)
  • the efficacy of the combination therapy is well demonstrated by large-scale studies, regardless of initial therapy or refractory/relapsed status ( N Engl J Med 372(2) (2015)">16 - Blood 131(3) (2018)">22 ). (cancerdiagnosisprognosis.org)
  • Although lenalidomide is considered to exert dual antitumor effects, including the activation of normal immune system through the activation of cytotoxic lymphocytes and the proteasome-dependent degradation of transcription factors such as IKZF1 and IKZF3 in myeloma cells ( J Mol Med (Berl) 94(12) (2016)">13 - Blood Rev 24(Suppl 1) (2010)">15 ), there is no clinical evidence that directly proves the association between changes in the profile of immune system and treatment efficacy in patients with MM treated with this agent. (cancerdiagnosisprognosis.org)
  • Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. (myeloma.org.uk)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Mitka M: New oversight put in place for physicians giving anemia drugs to patients with cancer. (karger.com)
  • Courneya KS, Jones LW, Peddle CJ, Sellar CM, Reiman T, Joy AA, Chua N, Tkachuk L, Mackey JR: Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial. (karger.com)
  • Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice. (cancernetwork.com)
  • The introduction of this generic equivalent will provide patients and clinicians with access to more choices for their cancer care. (fresenius-kabi.com)
  • Blood Cancer Journal 2016 May 13;6:e422. (fredhutch.org)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • In his early career Dr. Cogle discovered that blood stem cells make blood vessels and used that biology to invent new therapeutics and diagnostics for people with cancer and heart disease. (ufl.edu)
  • 3] IPSS is explicitly used by clinical guidelines such as those published by the National Comprehensive Cancer Network (NCCN) to help inform the choice of therapy for MDS patients. (org.in)
  • Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
  • The transplanted cells kill any remaining cancer cells and restore the patient's immune system. (mdanderson.org)
  • Large numbers of myeloid-derived suppressor cells (MDSCs), a mixture of monocytic and granulocytic cells, accumulate during many pathologic conditions, including cancer, infectious diseases, trauma, and sepsis. (biomedcentral.com)
  • increased number of NK cells (particularly mature NK cells), helper T cells, and depleted Tregs can positively affect clinical outcomes ( Cancer Biomark 24(4) (2019)">4 - Leuk Res 66 (2018)">10 ). (cancerdiagnosisprognosis.org)
  • Blood Cancer J. 2022 Mar 28;12(3):47. (gitmo.it)
  • Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
  • The donor immune cells can kill the leftover cancer cells and will exert a "graft-versus-cancer" effect, keeping the cancer cells in check. (parkwaycancercentre.com)
  • These cells can self-renew and the patient can enjoy a long-term cure from blood cancer. (parkwaycancercentre.com)
  • 3: Mörner M, Gunnarsson U, Jestin P, Egenvall M. Volume of blood loss during surgery for colon cancer is a risk determinant for future small bowel obstruction caused by recurrence--a population-based epidemiological study. (cancercentrum.se)
  • This leads to mobilization of hematopoietic stem cells to the peripheral blood. (drugs.com)
  • According to our data, numbers of SSClo ALDH(br) cells are in very good agreement with numbers of SSClo CD45(dim) CD34(hi) cells and can be a predictor of stem cell mobilization. (ogu.edu.tr)
  • The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34 + cell levels in peripheral blood, leukapheresis (LP) delays, overall number of LP sessions, and the rate of rescue mobilization with plerixafor. (biomedcentral.com)
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
  • PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
  • This pharmacologically induced egress of HSCs into peripheral blood, called mobilization, is utilized as the preferred strategy for generating HSCs for transplantation. (bdbiosciences.com)
  • Pretargeted Radioimmunotherapy for B-cell Lymphomas. (fredhutch.org)
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • We look forward to other payers recognizing the clinical benefits of lumbar TDR enabling patients to maintain spinal motion and avoid adjacent segment disease. (ukpropertyguides.com)
  • Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). (biomedcentral.com)
  • 2] Standard for describing populations of patients participating in pivotal clinical trials for MDS, including those that led to the approval of lenalidomide, azacitidine, and decitabine in most countries around the world. (org.in)
  • Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. (smw.ch)
  • Observing the everyday advancements in stem cell technology from the research and clinical perspective, stem cells do promise a healthy future for the coming generations in India. (advancells.com)
  • Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
  • Cell-based therapy using systemic infusion of GMSC in experimental colitis significantly ameliorated both clinical and histopathological severity of the colonic inflammation, restored the injured gastrointestinal mucosal tissues, reversed diarrhea and weight loss, and suppressed the overall disease activity in mice. (ca.gov)
  • We examined the clinical outcome of three autologous PDLP-treated patients in an effort to provide primary knowledge on the effectiveness of this treatment approach and preliminary clinical evidence for randomized controlled trial in the future. (ca.gov)
  • We describe in detail the clinical features, treatment, and outcomes of immunocompromised patients hospitalized in 6 tertiary centers in Australia during winter 2009. (cdc.gov)
  • Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. (myeloma.org.uk)
  • The following is a list of myeloma clinical trials at this center. (sparkcures.com)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • [ 32 ] The failure to demonstrate improved survival may be due to the small number of patients studied. (medscape.com)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • The final analysis of the landmark French IFM-94 trial demonstrated that double transplantation led to improved survival compared with single transplantation in patients with previously untreated myeloma. (cancertreatmenttoday.org)
  • Survival of ethnic and racial minority patients with multiple myelomatreated with newer medications. (myeloma.org.uk)
  • IMiDs are known to enhance the immune system by NK cell expansion and activation, regulatory T cell (Treg) inhibition, and/or restoration of T cell function in in vitro studies ( J Mol Med (Berl) 94(12) (2016)">13 - Blood Rev 24(Suppl 1) (2010)">15 ). (cancerdiagnosisprognosis.org)
  • Blood Adv. 2019;3(20):3123-3131. (stembook.org)
  • Methods: This retrospective study included 1344 patients with 1539 consecutive colorectal lesions who underwent ESD between September 2003 and December 2019. (bvsalud.org)
  • The Korean Multiple Myeloma Working Party (2019). (elsevierpure.com)
  • Also, the incidence of patients experiencing rejection is very rare (and graft-versus-host disease impossible) due to the donor and recipient being the same individual. (wikipedia.org)
  • Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. (uchicago.edu)
  • We conclude that in spite of rapid engraftment, non-hematological toxicities and infections remain important limitations for further reduction of the length of patient hospitalization in a significant number of patients after PBSCT. (nature.com)
  • The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed. (biomedcentral.com)
  • Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. (stembook.org)
  • Cord blood transplantation involves the use of stem cells from umbilical cord blood, which is collected and stored at birth. (koruhastanesi.com)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
  • Normal mature B cells are expected to have IgM and immunoglobulin D (IgD) on their surfaces, and, with proper stimulation, rearrange their immunoglobulin genes to switch from expressing IgM to IgG, IgA, or immunoglobulin E (IgE). (medscape.com)
  • Some patients are capable of normal antibody responses of other immunoglobulin classes following specific immunization, whereas others respond poorly. (medscape.com)
  • Immunoglobulin testing may be indicated for patients developing repeated infections. (medscape.com)
  • We also investigated the relationship between the number of SSClo CD45(dim) CD34(hi) cells, SSClo ALDH(br) cells and engraftment. (ogu.edu.tr)
  • Shortly after conditioning, LPI levels were increased in 23 patients, with peak at day 0, returning to normal range upon engraftment in 21 patients. (karger.com)
  • 0.05) while GIT toxicity was the most common reason for discharge delays in patients conditioned with melfalan 200 mg/m 2 (8.2% vs 14.7%, NS). (nature.com)
  • Moreover, none of the patients with an EF less than 50% developed cardiac toxicity. (slideshare.net)
  • Although the occurrence of cardiac toxicity is correlated with a reduction of EF before BMT, life-threatening cardiac toxicity cannot be predicted in individual patients [33]. (slideshare.net)
  • Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. (myeloma.org.uk)
  • A single dose of motixafortide results in achievement of stem cell collection goal in patients with multiple myeloma. (cancernetwork.com)
  • We could not find a relationship between the transplanted SSClo CD45(dim) CD34(hi) cell dose or SSClo ALDH(br) cell dose and platelet or neutrophil recovery. (ogu.edu.tr)
  • An accurate measurement of CD34 is critical for dose requirement protocols in stem cell transplantation. (bdbiosciences.com)
  • 5 An incorrectly high result could lead to an infusate with less than the recommended threshold dose of CD34+ cells. (bdbiosciences.com)
  • Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy. (myeloma.org.uk)
  • Administration of low-dose cytarabine results in immediate S-phase arrest and subsequent activation of cell cycling in murine stem cells. (rug.nl)
  • Candidates for HSCTs include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia with defective stem cells, and also children or adults with aplastic anemia who have lost their stem cells after birth. (wikipedia.org)
  • The optimal thresholds for SSClo CD45(dim) CD34(hi) cells were 5.40 x 106/kg for neutrophil recovery and 7.22 x 106/kg for platelet recovery. (ogu.edu.tr)
  • The optimal thresholds for SSClo ALDH(br) cells were 6.53 x 106/kg for neutrophil recovery and 8.72 x 106/kg platelet recovery. (ogu.edu.tr)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • In the state of Victoria, after the initial 3 months of community transmission of pandemic (H1N1) 2009 virus, 50% of patients who died had an underlying hematologic malignancy ( 15 ). (cdc.gov)
  • Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity. (myeloma.org.uk)
  • The IPSS, first published in 1997 and subsequently validated, has become the most widely adopted predictor of prognosis for patients with MDS. (org.in)
  • Despite antifungal therapy, the subcutaneous nodule on his left sole gradually enlarged, his left calcaneal bone was invaded, and the patient finally underwent amputation of his left leg. (bvsalud.org)
  • Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received. (cancernetwork.com)
  • Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments. (cancernetwork.com)
  • This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
  • The ORR was 64% in patients with prior T-cell redirecting therapy. (medscape.com)
  • The American Society for Transplantation and Cellular Therapy (ASTCT) guidelines recommend a collection target of 3-5 × 10 6 CD34+ cells/kg. (medscape.com)
  • Minimal residual disease (MRD) refers to the small number of malignant cells that remain after therapy when the patient is in remission and shows no symptoms or overt signs of disease. (smw.ch)
  • Physicians must understand both the natural history of multiple myeloma (MM) and the limitations of current therapy in the treatment of the disease. (medscape.com)
  • Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation. (bu.edu)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • Stem cell treatment has been widely accepted as the future of medical technology, therapy and any kind of treatment for health hazards. (advancells.com)
  • Often patients who have no conventional treatment left fell prey to such establishments and loose large amount of money without getting proper therapy, and therefore, no results. (advancells.com)
  • It is important for the patient to answer the basic questions of whether I am a candidate for stem cell therapy, (2) What kind of cells do I need? (advancells.com)
  • Before approaching any therapy provider, patients must do a thorough research on their credentials and whether a disease-specific specialist is going to perform / supervise therapy or not. (advancells.com)
  • At present, only guidelines are doing the rounds, which have resulted in the escalation of many clinics, hospitals, and nursing homes, claiming successful treatment by stem cell therapy. (advancells.com)
  • Two hundred thirty-one patients with symptomatic myeloma were enrolled in Total Therapy I between 1990 and 1995 (Barlogie et al. (cancertreatmenttoday.org)
  • Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. (frontiersin.org)
  • Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a recently described adverse side effect of bisphosphonate therapy, with an estimated 94% of cases reported in the oncologic patients receiving intravenous nitrogen-containing bisphosphonates (BP). (ca.gov)
  • Over the last few years, multiple reports have unveiled an association between anti-angiogenic therapy and TMA. (biomedcentral.com)
  • Oseltamivir resistance in 4 (13.3%) of 30 patients who were administered oseltamivir highlights the need for ongoing surveillance of such resistance and further research on optimal antiviral therapy in the immunocompromised. (cdc.gov)
  • Hematologists' Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment. (myeloma.org.uk)
  • A small number of stem cells can be found in the blood, and these can be collected for stem cell therapy. (parkwaycancercentre.com)
  • Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. (gitmo.it)
  • A 59-year-old man with a history of IgG kappa multiple myeloma presented to an outpatient facility for evaluation of left hip pain, which was found to be a pathologic fracture. (medscape.com)
  • Despite further resuscitative efforts, the patient died 13 hours after his initial presentation at the outpatient facility. (medscape.com)